Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More

Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More